A61P 3/08
Drugs for disorders of the metabolism: for glucose homeostasis
Official title: for glucose homeostasis (pancreatic hormones A61P5/48)
A61P3/08 (Drugs for disorders of the metabolism: for glucose homeostasis) appears on 28,531 US grants and 44,367 published applications in this corpus.
Search patents in A61P- Granted patents
- 28,531
- Published applications
- 44,367
- Assignees
- 9,020
- Inventors
- 58,856
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 7 | 0 |
| 1978 | 11 | 0 |
| 1979 | 17 | 0 |
| 1980 | 24 | 0 |
| 1981 | 27 | 0 |
| 1982 | 28 | 0 |
| 1983 | 16 | 0 |
| 1984 | 27 | 0 |
| 1985 | 29 | 0 |
| 1986 | 32 | 0 |
| 1987 | 31 | 0 |
| 1988 | 33 | 0 |
| 1989 | 42 | 0 |
| 1990 | 38 | 0 |
| 1991 | 47 | 0 |
| 1992 | 55 | 0 |
| 1993 | 47 | 0 |
| 1994 | 58 | 0 |
| 1995 | 71 | 0 |
| 1996 | 99 | 0 |
| 1997 | 155 | 0 |
| 1998 | 243 | 0 |
| 1999 | 248 | 0 |
| 2000 | 319 | 0 |
| 2001 | 419 | 165 |
| 2002 | 532 | 800 |
| 2003 | 581 | 1420 |
| 2004 | 503 | 1858 |
| 2005 | 550 | 1903 |
| 2006 | 773 | 1959 |
| 2007 | 832 | 2115 |
| 2008 | 930 | 2403 |
| 2009 | 1099 | 2754 |
| 2010 | 1521 | 3197 |
| 2011 | 1599 | 2983 |
| 2012 | 1796 | 2617 |
| 2013 | 1997 | 2177 |
| 2014 | 1990 | 2305 |
| 2015 | 1706 | 2020 |
| 2016 | 1414 | 1940 |
| 2017 | 1481 | 1754 |
| 2018 | 1249 | 1573 |
| 2019 | 1158 | 1607 |
| 2020 | 1105 | 1344 |
| 2021 | 920 | 1195 |
| 2022 | 678 | 1090 |
| 2023 | 584 | 942 |
| 2024 | 543 | 906 |
| 2025 | 541 | 816 |
| 2026 | 321 | 524 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Benzimidazole compound for the treatment of metabolic disorders29 Sep 2026US 12,746,227 B2Ache Laboratorios Farmaceuticos S/A
- Dynamic-covalent hydrogels with glucose-specific and glucose-responsive diboronate crosslinking29 Sep 2026US 12,746,277 B2University of Notre Dame du Lac
- Notch signaling inhibitors for treating obesity and metabolic disorders22 Sep 2026US 12,740,989 B2Purdue Research Foundation
- Composition for preventing, ameliorating, or treating metabolic syndromes including obesity, diabetes, hyperlipidemia, and fatty liver22 Sep 2026US 12,741,007 B2Nutracore Co., Ltd.
- Insulin-Fc fusion proteins and methods of use to treat cancer22 Sep 2026US 12,742,000 B2Akston Biosciences Corporation
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Antidiabetic pharmaceutical composition1 Oct 2026US 2026/0294823 A1Imam Abdulrahman Bin Faisal University
- Methods for the treatment of childhood-onset fluency disorder1 Oct 2026US 2026/0294924 A1Noema Pharma AG
- Pharmaceuticl compositions comprising bile acid compounds for oral delivery of therapeutic peptides1 Oct 2026US 2026/0294936 A1Waterstone Pharmaceuticals(Wuhan) Co., Ltd.
- Uses of super-oxide dismutase supplements1 Oct 2026US 2026/0295019 A1
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Diabetes management system1,937US 6,544,212 B2Roche Diagnostics GmbH · 2003
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004